Why must anakinra continue in adult-onset Still's disease after fever resolves and ferritin normalizes?

The single most consequential AOSD adherence error is stopping anakinra when the patient's ferritin drops from a peak of fifty thousand or eighty thousand nanograms per milliliter to near-normal and fever resolves — reasoning, correctly, that the labs show clear improvement and the drug appears to have done its job. This reasoning accurately describes what the drug has accomplished. It fatally misidentifies what the normalized ferritin means about the state of the underlying disease. Ferritin in AOSD is not a primary disease marker like CRP in rheumatoid arthritis. It is a hepatocyte transcriptional product whose production is directly driven by IL-1beta. In AOSD, hyperactivated macrophages, monocytes, and natural killer cells contain constitutively primed NLRP3 inflammasomes — the macromolecular platform that, when triggered by potassium efflux, mitochondrial reactive oxygen species, or lysosomal rupture from phagocytosed inflammatory debris, recruits and activates caspase-1. Activated caspase-1 cleaves the precursor pro-IL-1beta to the mature active IL-1beta that is secreted from the macrophage. Circulating IL-1beta binds IL-1 receptor type I on hepatocytes and activates NF-kB via the MyD88-IRAK-TRAF6 signaling complex, and NF-kB binding to IL-1-response elements in the ferritin heavy-chain gene 5-prime flanking region drives massive ferritin-H transcription. Ferritin levels correlate directly with IL-1beta activity in AOSD. Anakinra is a recombinant human IL-1 receptor antagonist: it competitively occupies IL-1 receptor type I on all cells, preventing both IL-1alpha and IL-1beta from binding. When anakinra blocks IL-1 receptor type I on hepatocytes, IL-1beta signaling through NF-kB to ferritin-H transcription is blocked: ferritin production falls, circulating ferritin normalizes over two to four weeks. The normalized ferritin is the pharmacodynamic signature of successful IL-1Ra therapy. It is not a marker of disease remission. The NLRP3 inflammasomes in the macrophages and NK cells are not less primed. The activated macrophage population that characterizes AOSD is not dissolved by anakinra — it is suppressed by continuous IL-1 receptor blockade. Anakinra has a subcutaneous half-life of four to six hours. It must be injected daily. A single missed day reduces receptor occupancy enough to permit partial IL-1beta receptor signaling. Stopping anakinra entirely removes all IL-1 receptor blockade within forty-eight hours. Within two to four weeks of anakinra cessation in active AOSD, IL-1beta production resumes, ferritin begins rising, fever returns. The specific danger unique to AOSD is macrophage activation syndrome — a form of secondary hemophagocytic lymphohistiocytosis. In AOSD, the tissue macrophages that are hyperactivated by the underlying disease biology have a particularly high propensity to develop uncontrolled proliferation and phagocytic activation when the IL-1 signaling circuit becomes unrestrained. MAS in AOSD is characterized by hyperferritinemia often above ten thousand — and frequently above one hundred thousand nanograms per milliliter — falling white blood cell count, falling platelet count (thrombocytopenia from phagocytosis), rising triglycerides, rising fibrinogen followed by consumption coagulopathy with falling fibrinogen and rising D-dimer, rising LDH, and hemophagocytosis on bone marrow biopsy showing macrophages engulfing red blood cells, white cells, and platelets. The cytokine responsible for the transition from controlled AOSD to MAS is IL-18, a second IL-1 family cytokine also processed by NLRP3-activated caspase-1 to its active form. IL-18 drives interferon-gamma production from NK cells and T cells, and interferon-gamma drives macrophage hyperactivation and hemophagocytosis in a self-amplifying loop. MAS mortality in AOSD even with ICU care and combination immunosuppression is ten to twenty percent. Anakinra suppresses the upstream NLRP3-caspase-1 amplification loop that produces both IL-1beta and the trigger for IL-18-driven NK cell activation. When anakinra is stopped, this suppression is removed. Spanish frame: 'La ferritina normalizada y la fiebre que desapareció son exactamente lo que buscamos cuando iniciamos el anakinra. Eso quiere decir que el medicamento está bloqueando la señal de IL-1beta que activaba la producción de ferritina en el hígado. Es la prueba de que el medicamento funciona. El problema es que las células del sistema inmune — los macrófagos que son el origen de esa señal — no se han vuelto normales. Están siendo controlados por el medicamento. Cuando se para el anakinra, esa señal de IL-1beta regresa en días. Y en su enfermedad hay un riesgo específico cuando esa señal se descontrola — una complicación que se llama síndrome de activación macrofágica, que es una tormenta de citoquinas muy severa con mortalidad del diez al veinte por ciento incluso cuando se trata en la unidad de cuidados intensivos. Los beneficios económicos de parar el medicamento no compensan ese riesgo.' (The normalized ferritin and the fever that disappeared are exactly what we seek when we start anakinra. That means the medication is blocking the IL-1beta signal that was activating ferritin production in the liver. It is proof the medication is working. The problem is that the immune cells — the macrophages that are the source of that signal — have not returned to normal. They are being controlled by the medication. When anakinra is stopped, that IL-1beta signal returns within days. And in your disease there is a specific risk when that signal becomes uncontrolled — a complication called macrophage activation syndrome, which is a very severe cytokine storm with mortality of ten to twenty percent even when treated in the intensive care unit. The economic benefit of stopping the medication does not offset that risk.)

What is the chronic articular phenotype of adult-onset Still's disease and why must methotrexate continue after systemic features resolve?

Adult-onset Still's disease does not follow a single clinical course. Research in AOSD cohorts has established three phenotypic trajectories that differ in natural history, mechanism, and treatment requirement. The first phenotype is the systemic self-limited form: a single episode of fevers, rash, serositis, and elevated ferritin that resolves completely — with or without treatment — within twelve months and does not recur. In this form, the NLRP3-IL-1beta-IL-18 innate immune amplification loop activates, produces the systemic flare, and self-extinguishes. The second phenotype is systemic recurrent: intermittent systemic flares separated by periods of clinical remission, each flare driven by the same NLRP3-IL-1beta machinery, each potentially carrying MAS risk. The third phenotype — the chronic articular form — is the most clinically insidious. In this form, the systemic features (fever, salmon rash, serositis, hyperferritinemia) may resolve within the first several months of treatment, but a persistent synovitis establishes itself in the wrists, metacarpophalangeal joints, proximal interphalangeal joints, and ankles. This synovitis is no longer primarily driven by the IL-1beta-IL-18 innate pathway of the systemic phase — it transitions to a T cell-mediated, IL-17 and TNF-alpha-dominated adaptive immune synovitis that histologically resembles seropositive rheumatoid arthritis: pannus formation, synovial hyperplasia with villous projections, plasma cell and CD4-positive T cell infiltration, and rice bodies (fibrin-containing membrane fragments in the synovial fluid, characteristic of AOSD synovitis) visible on high-resolution musculoskeletal ultrasound. The patient and often the clinician who focuses on the systemic features may interpret the resolution of fever and fall in ferritin as overall disease remission, not recognizing that a different inflammatory program has taken over in the joints. Methotrexate at fifteen to twenty milligrams per week works by two mechanisms relevant to this persistent synovitis. First, DHFR inhibition depletes intracellular tetrahydrofolate, impairing the proliferative capacity of rapidly dividing synovial T cells and B cells. Second, methotrexate at therapeutic doses causes adenosine release at the synovial membrane through accumulation of upstream folate pathway intermediates, and adenosine acting on A2A receptors on synoviocytes and macrophages raises intracellular cAMP and suppresses NF-kB-mediated TNF-alpha and IL-6 production. When methotrexate is stopped because systemic features have resolved, these two mechanisms of synovial protection are removed. The chronic articular synovitis continues through the persistent T cell and TNF-alpha program. Rice-body synovitis in the carpal joints and MCPs deposits fibrin fragments that are not reabsorbed. Pannus at the MCP and wrist joints activates RANKL-dependent osteoclasts at marginal erosion sites. Annual hand and wrist x-rays detect marginal erosions, carpus sclerosis, and joint space narrowing that precede symptoms. The AOSD clinic nurse who encounters a patient with stabilized systemic features who has stopped or wants to stop methotrexate must know the phenotype classification and identify whether the patient is in the systemic-self-limited trajectory (in which stopping DMARD at twelve months of remission may be appropriate) or the chronic articular trajectory (in which stopping DMARD produces silent ongoing erosion). Musculoskeletal ultrasound of the wrists and MCPs — showing Power Doppler synovial hyperemia and rice-body deposits — differentiates active chronic articular AOSD from true remission. Spanish frame: 'La enfermedad de Still en adultos puede tomar tres formas. La primera forma: el episodio sistémico — la fiebre, el sarpullido, la serositis — ocurre una vez y se resuelve completamente. La segunda: el episodio sistémico ocurre y recurre en episodios. La tercera — y es la que parece ser su caso — se llama la forma articular crónica: los síntomas sistémicos se resolvieron, que es bueno, pero hay una inflamación persistente en las articulaciones de las muñecas y los nudillos que continúa a través de un mecanismo diferente — ya no es IL-1beta sino células T y TNF. Esa inflamación, si no se trata, produce erosión silenciosa en los huesos de las muñecas y los nudillos que la radiografía detecta pero que no necesariamente duele hasta que el daño es importante. El metotrexato que usted tomaba estaba suprimiendo precisamente esa inflamación articular. Cuando lo paró, ese proceso volvió a su ritmo habitual. Necesitamos reiniciarlo y hacer una ecografía de las articulaciones para ver cuánto ha progresado desde que lo paró.' (Still's disease in adults can take three forms. The first form: the systemic episode — the fever, the rash, the serositis — occurs once and resolves completely. The second: the systemic episode occurs and recurs. The third — and this appears to be your case — is called the chronic articular form: the systemic symptoms resolved, which is good, but there is persistent inflammation in the wrist and knuckle joints that continues through a different mechanism — no longer IL-1beta but T cells and TNF. That inflammation, if untreated, produces silent erosion in the wrist and knuckle bones that x-ray detects but that does not necessarily hurt until the damage is significant. The methotrexate you were taking was suppressing exactly that joint inflammation. When you stopped it, that process returned to its usual pace. We need to restart it and do a joint ultrasound to see how much has progressed since you stopped.)

Why is the salmon-colored evanescent rash of adult-onset Still's disease a sign of active disease even when it disappears on prednisone?

The salmon-colored rash of AOSD is one of the most diagnostically distinctive findings in medicine and one of the most misunderstood by patients in its relationship to treatment adequacy. The rash has two characteristics that together explain why its disappearance on prednisone cannot be interpreted as remission. First, it is evanescent by mechanism: the salmon-colored urticarial wheals typically appear in the late afternoon and evening when the daily quotidian fever spike occurs, are present for twenty to sixty minutes as body temperature peaks, and then fade as the fever spike subsides and inter-spike afebrile status resumes. They may return the following afternoon with the next fever spike. They may be present and absent multiple times within a single twenty-four-hour period. A patient who checks for the rash in the morning — when AOSD fevers are at their daily nadir — may see no rash and conclude the disease is improving, when in fact the neutrophilic urticarial rash returns each afternoon with each quotidian fever spike. Second, the mechanism of the rash is distinct from classical urticaria. The salmon wheals of AOSD are not mast-cell-degranulation histaminergic urticaria. They are a neutrophilic urticarial dermatosis: the dermal infiltrate on biopsy shows primarily neutrophils and occasional eosinophils without the eosinophil-rich perivascular infiltrate of classical allergic urticaria. IL-18 — the second IL-1 family cytokine produced by NLRP3-activated caspase-1 in AOSD — is the primary driver of this neutrophilic skin infiltration. IL-18 activates T cells and NK cells to produce interferon-gamma, and interferon-gamma activates keratinocytes to upregulate ICAM-1 and produce CXCL8 (IL-8), a potent neutrophil chemoattractant. IL-18 also directly activates neutrophil degranulation and NET (neutrophil extracellular trap) formation, releasing elastase, myeloperoxidase, and citrullinated histone H3 into the dermal interstitium, producing the wheals. The wheals coincide temporally with the fever spike because it is the same underlying IL-18-IL-1beta surge that produces both the hypothalamic fever response via prostaglandin E2 and the dermal neutrophil activation. Prednisone suppresses neutrophil trafficking and CXCL8 production through glucocorticoid receptor binding to NF-kB and AP-1, reducing IL-18-driven neutrophil skin migration and eliminating the visible rash. But prednisone at standard doses does not significantly suppress NLRP3 inflammasome activation or caspase-1-mediated IL-1beta and IL-18 production at the macrophage and NK cell level — that is precisely why IL-1Ra (anakinra) is more effective than prednisone at preventing MAS in AOSD. When the salmon rash disappears on prednisone, it means the glucocorticoid has blocked neutrophil CXCL8-driven skin trafficking. The underlying NLRP3-caspase-1-IL-18-IL-1beta circuit in the macrophages remains active. The rash disappearing is not a reliable marker of remission. The appropriate marker of remission in AOSD is normalization of ferritin, normalization of white blood cell count, resolution of all systemic features (fever, serositis, arthritis, hepatosplenomegaly), and sustained normalization of inflammatory markers for a minimum of six to twelve months. Prednisone taper for a first systemic AOSD flare should follow a structured schedule: after four to six weeks at full therapeutic dose, reduce by no more than ten percent of the current dose every two to four weeks, targeting complete taper over twelve months. Self-tapering based on rash disappearance at three weeks — as Sofía did — removes the anti-inflammatory protection at a time when the macrophage activity driving the systemic disease has not been suppressed, risks IL-1beta rebound and MAS trigger, and in the setting of new pericarditis carries specific risk of pericardial effusion progression to tamponade. Spanish frame: 'El sarpullido rosado salmón de la enfermedad de Still es una de las características más típicas de esta enfermedad, y entiendo por qué su desaparición se ve como una buena señal. Pero este sarpullido tiene dos características que quiero explicarle. La primera: desaparece naturalmente de todas formas, incluso sin tratamiento, porque aparece con cada pico de fiebre y se va cuando la fiebre baja. Aparece por la tarde o la noche cuando la temperatura sube, y desaparece en minutos o una hora cuando la temperatura baja. Si usted no tiene fiebre en ese momento, tampoco tiene el sarpullido. La segunda: el sarpullido desaparece con prednisona porque la prednisona bloquea la señal que lleva a los neutrófilos a la piel. Pero los macrófagos y las células NK que producen las citoquinas que causan toda la enfermedad — la fiebre, la artritis, la serositis — siguen activos. La prednisona los controla parcialmente, pero no los apaga. Para que la enfermedad entre en verdadera remisión necesitamos que la ferritina baje, que todos los síntomas sistémicos se resuelvan, y que se mantengan controlados durante al menos seis meses. Reducir la prednisona en unas semanas porque el sarpullido desapareció retira la protección demasiado pronto y puede desencadenar una recaída severa — incluyendo una complicación grave que afecta el corazón y que usted ya comenzó a desarrollar.' (The salmon-pink rash of Still's disease is one of the most typical characteristics of this disease, and I understand why its disappearance looks like a good sign. But this rash has two characteristics I want to explain to you. The first: it disappears naturally on its own even without treatment, because it appears with each fever spike and goes away when the fever drops. It appears in the afternoon or evening when temperature rises, and disappears in minutes or an hour when temperature falls. If you do not have fever at that moment, you also do not have the rash. The second: the rash disappears with prednisone because prednisone blocks the signal that brings neutrophils to the skin. But the macrophages and NK cells that produce the cytokines that cause all the disease — the fever, the arthritis, the serositis — remain active. Prednisone controls them partially, but does not turn them off. For the disease to enter true remission we need the ferritin to fall, all systemic symptoms to resolve, and to remain controlled for at least six months. Reducing prednisone in a few weeks because the rash disappeared withdraws protection too soon and can trigger a severe relapse — including a serious complication affecting the heart that you had already begun to develop.)

What is macrophage activation syndrome in adult-onset Still's disease and how do nurses explain its risk in Spanish?

Macrophage activation syndrome is the most feared complication of adult-onset Still's disease and the reason that treatment adherence has life-or-death stakes in AOSD in a way that differs from most other inflammatory arthropathies. It is a form of secondary hemophagocytic lymphohistiocytosis — a state of uncontrolled immune activation in which tissue macrophages are hyperproliferating, hyperactivated, and performing pathological hemophagocytosis (engulfing red blood cells, platelets, and white blood cells in the bone marrow, spleen, and liver). MAS in AOSD is mechanistically distinct from the primary HLH of inherited NK cell and T cell cytotoxicity defects: it is driven by the same NLRP3-caspase-1 machinery of AOSD, specifically through the AOSD overproduction of IL-18. In AOSD, serum IL-18 levels are among the highest recorded in any inflammatory disease — often ten to fifty times above normal — reflecting the intense NLRP3 inflammasome activation and caspase-1 activity in the activated macrophage and NK cell pool. IL-18 drives NK cell interferon-gamma production in a caspase-1-dependent manner, and interferon-gamma is the master activator of macrophage hyperactivation and hemophagocytosis: it activates the AP-1 and STAT1 signaling programs in macrophages that upregulate phagocytic receptors, drive proliferative macrophage expansion, and suppress macrophage apoptosis. The IL-18-interferon-gamma-macrophage circuit creates a self-amplifying positive feedback loop: activated macrophages producing more IL-18, more interferon-gamma, more macrophage activation. The clinical presentation of MAS includes a rapid rise in ferritin — often exceeding ten thousand and frequently exceeding one hundred thousand nanograms per milliliter — simultaneous fall in white blood cell count, red blood cell count, and platelet count despite the underlying inflammatory disease (cytopenias in an inflammatory disease are paradoxical and specifically suggest MAS/HLH), rising triglycerides from interferon-gamma-mediated inhibition of lipoprotein lipase, rising D-dimer and fibrinogen consumption from disseminated intravascular coagulation, rising ALT and AST from hepatic macrophage infiltration, splenomegaly, and hemophagocytosis on bone marrow biopsy. The HScore clinical scoring system (incorporating nine variables including ferritin, cytopenias, triglycerides, fibrinogen, splenomegaly, and immune suppression status) estimates probability of HLH/MAS and guides ICU management. Treatment of AOSD-associated MAS typically requires combination high-dose methylprednisolone pulse, cyclosporine A (which suppresses T cell-derived interferon-gamma), and anakinra or high-dose tocilizumab (anti-IL-6), and in refractory cases emapalumab (anti-interferon-gamma monoclonal antibody). Plasmapheresis is used in cytokine storm management. Mortality ten to twenty percent even with full ICU management. For AOSD clinic nurses, the key teaching for Spanish-speaking patients is the difference between a controllable disease and a life-threatening complication: 'La enfermedad de Still en adultos puede controlarse bien con el tratamiento adecuado — como usted vio cuando la fiebre y los análisis mejoraron. Pero hay una complicación de esta enfermedad que se llama síndrome de activación macrofágica que puede ocurrir si el tratamiento se interrumpe o si la enfermedad no está bien controlada. En ese síndrome, las células del sistema inmune que ya están muy activas en su enfermedad empiezan a multiplicarse y a destruir los componentes de la sangre — glóbulos rojos, blancos y plaquetas — al mismo tiempo que producen una tormenta de inflamación que puede afectar el hígado, los pulmones y el cerebro. Tiene una mortalidad del diez al veinte por ciento incluso cuando se trata en cuidados intensivos. La ferritina es el marcador que nos avisa: cuando sube muy rápido — a cincuenta mil, ochenta mil, cien mil — es la señal de que esa complicación puede estar comenzando. El medicamento que usted toma — el anakinra — protege específicamente contra esa complicación al bloquear las señales que la desencadenan. Por eso su continuidad sin interrupciones es tan importante.' (Still's disease in adults can be well controlled with appropriate treatment — as you saw when the fever and lab tests improved. But there is a complication of this disease called macrophage activation syndrome that can occur if treatment is interrupted or if the disease is not well controlled. In that syndrome, the immune cells that are already very active in your disease start multiplying and destroying the components of the blood — red cells, white cells, and platelets — while producing an inflammatory storm that can affect the liver, lungs, and brain. It has a mortality of ten to twenty percent even when treated in intensive care. Ferritin is the marker that warns us: when it rises very rapidly — to fifty thousand, eighty thousand, one hundred thousand — it is the sign that this complication may be beginning. The medication you take — anakinra — protects specifically against that complication by blocking the signals that trigger it. That is why its uninterrupted continuation is so important.)

What are the key Spanish phrases for adult-onset Still's disease clinic nurses explaining IL-1 blockade continuation, chronic articular phenotype, and safe prednisone tapering?

For explaining why anakinra must continue after ferritin normalizes: 'La ferritina normal y la fiebre que desapareció son la prueba de que el anakinra está funcionando — no la prueba de que la enfermedad desapareció. La célula del sistema inmune que produce la señal que causaba esa fiebre y esa ferritina alta sigue ahí, controlada por el medicamento. Cuando se para el anakinra, esa señal regresa en días. Y en la enfermedad de Still hay una complicación muy grave — el síndrome de activación macrofágica — que puede ocurrir cuando esa señal se descontrola. No podemos tomar ese riesgo porque el lab mejoró.' (The normal ferritin and the fever that disappeared are the proof that anakinra is working — not the proof that the disease disappeared. The immune cell that produces the signal that was causing that fever and high ferritin is still there, controlled by the medication. When anakinra is stopped, that signal returns within days. And in Still's disease there is a very serious complication — macrophage activation syndrome — that can occur when that signal becomes uncontrolled. We cannot take that risk because the lab improved.) For explaining the three AOSD phenotypes and the chronic articular form: 'La enfermedad de Still puede tomar tres formas. En una forma, los síntomas sistémicos — la fiebre, el sarpullido — ocurren una vez y se resuelven completamente. En otra forma, esos episodios vuelven de vez en cuando. En la tercera forma — que es la que usted tiene — los síntomas sistémicos mejoraron, pero las articulaciones de las muñecas y los nudillos desarrollaron una inflamación persistente que funciona de manera diferente: ya no es la misma señal IL-1 del episodio agudo, sino células T y TNF que pueden erosionar las articulaciones silenciosamente. El metotrexato protegía exactamente eso. Cuando lo paró, ese proceso siguió su curso.' (Still's disease can take three forms. In one form, the systemic symptoms — fever, rash — occur once and resolve completely. In another form, those episodes come back occasionally. In the third form — which is the one you have — the systemic symptoms improved, but the wrist and knuckle joints developed a persistent inflammation that works differently: no longer the same IL-1 signal of the acute episode, but T cells and TNF that can erode the joints silently. Methotrexate was protecting exactly that. When you stopped it, that process continued its course.) For explaining why prednisone taper must be slow in AOSD: 'La prednisona en la enfermedad de Still no se puede reducir según cómo uno se siente en el momento. En esta enfermedad específica, sentirse bien con prednisona no significa que la inflamación esté apagada — significa que la prednisona la está controlando. Si la prednisona se reduce muy rápido, la enfermedad puede regresar con más fuerza, incluyendo una complicación que afecta el corazón. El protocolo estándar es reducir muy lentamente — no más del diez por ciento de la dosis cada dos a cuatro semanas — y siempre en coordinación con el reumatólogo.' (Prednisone in Still's disease cannot be reduced based on how one feels at the moment. In this specific disease, feeling well on prednisone does not mean the inflammation is extinguished — it means prednisone is controlling it. If prednisone is reduced too quickly, the disease can return more forcefully, including a complication affecting the heart. The standard protocol is to reduce very slowly — no more than ten percent of the dose every two to four weeks — and always in coordination with the rheumatologist.) For explaining the evanescent rash: 'El sarpullido rosado salmón de la enfermedad de Still tiene una característica muy particular: aparece cuando sube la fiebre y desaparece cuando la fiebre baja, a veces en menos de una hora. Por eso se llama evanescente — va y viene. En la piel con prednisona, la prednisona bloquea los neutrófilos que producen ese sarpullido, así que el sarpullido se va. Pero la fuente del problema — las células que producen IL-18 e IL-1beta y que causan la fiebre, la artritis y los riesgos serios — sigue activa. El sarpullido que desaparece con prednisona es una señal de que la prednisona está haciendo algo, pero no es una señal confiable de remisión completa.' (The salmon-pink rash of Still's disease has a very particular characteristic: it appears when fever rises and disappears when fever falls, sometimes in less than one hour. That is why it is called evanescent — it comes and goes. In the skin with prednisone, prednisone blocks the neutrophils that produce that rash, so the rash goes away. But the source of the problem — the cells that produce IL-18 and IL-1beta and that cause the fever, arthritis, and serious risks — remains active. The rash disappearing with prednisone is a sign that prednisone is doing something, but it is not a reliable sign of complete remission.) For explaining ferritin monitoring: 'La ferritina en la enfermedad de Still es como un termómetro de la actividad de la enfermedad en el fondo. Cuando sube por encima de diez mil o cincuenta mil, es la señal más importante de que algo está pasando. Cuando está por encima de cien mil y al mismo tiempo los glóbulos blancos y las plaquetas están cayendo — esa es la señal de emergencia. Necesita venir a urgencias inmediatamente si tiene esos síntomas: fiebre que no cede, manchas en la piel por plaquetas bajas, o cualquier signo de sangrado inusual. No espere la próxima cita.' (Ferritin in Still's disease is like a thermometer of the underlying disease activity. When it rises above ten thousand or fifty thousand, it is the most important signal that something is happening. When it is above one hundred thousand and at the same time white cells and platelets are falling — that is the emergency signal. You need to come to the emergency room immediately if you have those symptoms: fever that does not respond, skin spots from low platelets, or any sign of unusual bleeding. Do not wait for the next appointment.)

November 3, 2026 · Rheumatology, Adult-onset Still’s Disease

Spanish for adult-onset Still’s disease clinic nurses — the patient who stopped anakinra when fever resolved and ferritin normalized not knowing IL-1Ra blockade must continue because macrophage activation syndrome carries 10–20% mortality; the patient who stopped methotrexate when joint swelling resolved not knowing the chronic articular phenotype erodes silently without DMARD; and the patient who self-tapered prednisone when the salmon rash disappeared not knowing the evanescent neutrophilic urticarial rash is IL-18 suppression not remission

Three conversations for adult-onset Still’s disease clinic nurses: Elena Herrera-Santos, 34, Los Angeles, who stopped anakinra when ferritin normalized not knowing that normalization is the drug working and that stopping removes the protection against macrophage activation syndrome; Carlos Medina-Ruiz, 44, Phoenix, who stopped methotrexate when joint swelling resolved not knowing the chronic articular phenotype of AOSD produces IL-17-TNF synovitis that erodes silently after systemic features quiet; and Sofía Ramos-Cisneros, 26, Chicago, who self-tapered prednisone when the salmon-colored rash disappeared not knowing the evanescent rash disappears on glucocorticoids by neutrophil suppression while the underlying NLRP3-IL-18-IL-1β circuit that can trigger MAS remains active.

Adult-onset Still’s disease presents the clinic nurse with a set of adherence challenges that are uniquely consequential: in AOSD, the misread treatment signal does not merely permit disease to progress asymptomatically — it can remove the protection against a cytokine storm that kills one in ten to one in five patients even with intensive care. The three errors in this post are structurally related: each patient reads a visible, measurable improvement — normalized ferritin, resolved joint swelling, disappeared rash — as evidence that the treatment objective has been achieved and the medication can be stopped. In AOSD, each of these inferences is wrong in a specific and mechanistically important way. And the stakes of the error are not silent joint erosion or slow structural progression — they are macrophage activation syndrome, pericardial tamponade, and a disease whose biology makes rapid clinical deterioration the rule rather than the exception when treatment is withdrawn prematurely.

Adult-onset Still’s disease is a systemic autoinflammatory disease — distinct from autoimmune diseases because it is driven by dysregulated innate immunity rather than adaptive autoimmunity. The central pathological event is hyperactivation of the NLRP3 inflammasome in macrophages, monocytes, and natural killer cells. Activated NLRP3 assembles the multiprotein inflammasome complex, recruits and activates caspase-1, and caspase-1 cleaves pro-IL-1β and pro-IL-18 to their active secreted forms. IL-1β drives the systemic features of AOSD: fever through prostaglandin E2-hypothalamic EP3 receptor signaling, acute-phase proteins through NF-κB activation in hepatocytes including the massive ferritin-H chain transcription that produces the characteristic extreme hyperferritinemia of AOSD, and serositis through pleural and pericardial mesothelial activation. IL-18 drives the dermal neutrophilic activation producing the salmon rash, and more critically, drives NK cell and T cell interferon-gamma production that feeds back into the macrophage-activation loop that — when uncontrolled — produces macrophage activation syndrome. Understanding this pathophysiology is the foundation of every AOSD adherence conversation, because every treatment decision and every stopping-decision maps directly onto this cascade.

Three patients, three structurally distinct adherence failures, and three conversations that each require the nurse to explain a different level of the same NLRP3-IL-1β-IL-18 architecture in Spanish.

Scenario 1: Elena Herrera-Santos — 34 years old, Los Angeles, California

Elena Herrera-Santos was a thirty-four-year-old pediatric home-health registered nurse in Los Angeles who knew more clinical medicine than most patients but found herself completely unprepared for the disease she developed. In February of the year prior, she noticed fevers beginning each evening — peaking between thirty-nine point eight and forty point one degrees Celsius between five in the afternoon and midnight, then breaking with diaphoresis in the early morning hours. She initially attributed the fevers to a viral illness. When they persisted into the third week, she noticed a faint salmon-pink rash on her trunk and upper arms that appeared as the fevers rose in the afternoon and faded by morning. Her wrists and right knee had swollen. Her fatigue was profound.

Her primary care physician ordered labs that returned dramatically abnormal: white blood cell count twenty-two thousand per microliter with left shift, CRP ninety-four milligrams per liter, ESR eighty-two, ferritin seventy-eight thousand nanograms per milliliter, alanine aminotransferase ninety-four units per liter, aspartate aminotransferase sixty-eight, and lactate dehydrogenase four hundred and twelve. Abdominal ultrasound showed hepatosplenomegaly. She had a pericardial friction rub on cardiac exam. ANA and RF were negative. The rheumatologist who evaluated her applied the 2016 Fautrel classification criteria for AOSD and made the diagnosis: five or more spiking fevers per week, evanescent rash, arthritis, leucocytosis above ten thousand with neutrophilia, negative ANA and RF, and serum ferritin above the upper limit of normal — she met all criteria definitively.

She was started on methylprednisolone forty milligrams daily intravenously for the first four days due to her pericardial effusion — eight millimeters on echocardiography — then transitioned to prednisone forty milligrams orally, and anakinra one hundred milligrams subcutaneously daily was added at week one given the severity of her presentation.

Eight weeks into treatment, Elena was dramatically improved. Fevers had fully resolved. The salmon rash had not appeared in three weeks. Her wrists and knee were no longer swollen. Her ferritin had fallen from seventy-eight thousand to eighteen hundred nanograms per milliliter. CRP was eleven — mildly elevated but not alarmingly so. She felt, in her words, almost like herself again. She was back to work part-time.

Between her eight-week visit and her scheduled twelve-week follow-up, she stopped anakinra. The reason was primarily financial: anakinra was costing her twelve hundred dollars per month after insurance, a cost she had managed during the acute phase but felt unjustified now that her labs showed clear improvement. She was also reassured by her own clinical knowledge — she knew her ferritin was falling and her fevers were gone. She planned to tell the rheumatologist at the next visit.

At three weeks off anakinra, Elena's fever returned. Not gradually — overnight, a quotidian spike to forty point two degrees Celsius. She recognized the pattern and called the rheumatology clinic the following morning. Nurse Adriana Morales-Fuentes took the call and immediately requested that Elena come in for urgent labs. The results were alarming: ferritin had spiked to one hundred and forty-five thousand nanograms per milliliter — nearly double her presenting level. Platelet count had fallen from two hundred and twenty thousand at her last visit to sixty-eight thousand. White blood cell count, which had normalized to nine thousand, had risen to twenty-six thousand. D-dimer was eight point four micrograms per milliliter. LDH was nine hundred and seventy. She was admitted directly from the clinic to the ICU with a diagnosis of AOSD-associated macrophage activation syndrome.

She survived, with three days of methylprednisolone pulse one gram daily, cyclosporine, and anakinra rechallenge at two hundred milligrams daily. She was discharged on day nine.

Nurse Morales-Fuentes had the most important conversation of Elena's disease course during the inpatient day three, when Elena was stable enough to talk about what had happened. Elena asked, straightforwardly: “¿Por qué ocurrió esto si los análisis mostraban que estaba mejorando? Si la ferritina bajó tanto, ¿eso no significa que la enfermedad se estaba yendo?”

(Why did this happen if the labs showed I was improving? If the ferritin fell so much, doesn’t that mean the disease was going away?)

“Esa es exactamente la pregunta correcta, y tiene sentido que lo hayas interpretado así. Pero la ferritina en tu enfermedad funciona de manera diferente a como pensamos. Cuando el anakinra estaba funcionando, bloqueaba una señal llamada IL-1beta que le ordena al hígado que produzca ferritina. Sin esa señal, el hígado la produce en cantidades mucho menores, y el número baja en los análisis. Eso es la ferritina bajando. Pero las células del sistema inmune que producían esa señal — los macrófagos y las células NK en tu sangre y tus tejidos — no desaparecieron. Estaban siendo controlados por el medicamento. Cuando paraste el anakinra, esa señal volvió a producirse libremente.”

(That is exactly the right question, and it makes sense that you interpreted it that way. But ferritin in your disease works differently from how we might think. When anakinra was working, it was blocking a signal called IL-1beta that tells the liver to produce ferritin. Without that signal, the liver produces much less, and the number falls in the labs. That is the ferritin falling. But the immune cells that were producing that signal — the macrophages and NK cells in your blood and tissues — did not disappear. They were being controlled by the medication. When you stopped anakinra, that signal was produced freely again.)

Elena: “Pero ¿por qué empeoró tan rápido? Subió de mil ochocientos a ciento cuarenta y cinco mil en tres semanas. No tenía eso antes de empezar el tratamiento.”

“Eso es la parte más importante de entender. En tu enfermedad — la enfermedad de Still — hay una complicación llamada síndrome de activación macrofágica. Lo que pasa es que cuando la señal IL-1beta se descontrola en esta enfermedad específica, activa otra señal que se llama IL-18, que hace que las células inmunes entren en un ciclo de amplificación: los macrófagos se multiplican, empiezan a destruir los glóbulos rojos, blancos y plaquetas dentro de la médula ósea, y producen cada vez más citoquinas que empeoran el ciclo. Es una tormenta que se alimenta a sí misma. La ferritina sube dramáticamente — a veces diez veces más que el valor de presentación — porque la inflamación ahora es de una naturaleza diferente y muchísimo más intensa. Las plaquetas bajan porque los macrófagos las están destruyendo. El anakinra bloqueaba precisamente esa amplificación. Sin él, el ciclo de amplificación empezó.”

(That is the most important part to understand. In your disease — Still’s disease — there is a complication called macrophage activation syndrome. What happens is that when the IL-1beta signal becomes uncontrolled in this specific disease, it activates another signal called IL-18, which causes immune cells to enter an amplification cycle: macrophages multiply, begin destroying red blood cells, white cells, and platelets inside the bone marrow, and produce more and more cytokines that worsen the cycle. It is a storm that feeds itself. Ferritin rises dramatically — sometimes ten times the presenting value — because the inflammation is now of a different and much more intense nature. Platelets fall because macrophages are destroying them. Anakinra was blocking exactly that amplification. Without it, the amplification cycle began.)

Elena: “¿Esto podría haberse evitado?”

“Sí. Si hubier as continuado el anakinra, la señal de IL-1beta habría permanecido bloqueada, y esta complicación no habría ocurrido — o habría tenido mucho menos probabilidad de ocurrir. El medicamento tenía que continuar. Pero quiero que sepas que esto no fue una decisión irresponsable de tu parte — fue una decisión basada en información incompleta sobre lo que significan los análisis en esta enfermedad. El trabajo del equipo clínico es darte esa información antes de que tomes esa decisión, no después. Cuando salgamos del hospital, vamos a tener una conversación muy clara sobre el significado de cada análisis y cuándo va a ser apropiado empezar a reducir el tratamiento — y ese proceso toma meses, no semanas.”

(Yes. If you had continued the anakinra, the IL-1beta signal would have remained blocked, and this complication would not have occurred — or would have had much lower probability of occurring. The medication had to continue. But I want you to know that this was not an irresponsible decision on your part — it was a decision based on incomplete information about what the lab values mean in this disease. It is the clinical team’s job to give you that information before you make that decision, not after. When we leave the hospital, we are going to have a very clear conversation about the meaning of each lab value and when it will be appropriate to begin reducing treatment — and that process takes months, not weeks.)

Elena recovered fully from the MAS episode. She continued anakinra for fourteen months, with her first cautious dose reduction at month twelve under close laboratory monitoring. Her ferritin at month fourteen was within normal limits on stable anakinra, and the plan for eventual off-therapy trial was made jointly by patient and rheumatologist with full understanding of the ferritin surveillance protocol and the threshold for emergency return.

Scenario 2: Carlos Medina-Ruiz — 44 years old, Phoenix, Arizona

Carlos Medina-Ruiz was a forty-four-year-old warehouse supervisor in Phoenix whose index AOSD episode had occurred eighteen months earlier. That episode had been textbook: three weeks of daily quotidian fevers peaking at thirty-nine point six degrees, the salmon evanescent rash appearing each evening on the trunk and thighs, bilateral wrist and metacarpophalangeal synovitis, right knee effusion, sore throat on presentation, and ferritin that reached forty-five thousand nanograms per milliliter at peak. He was admitted for the initial workup, tested negative for rheumatoid factor, ANA, anti-CCP, parvovirus, and EBV, and was diagnosed with AOSD by his rheumatologist.

He was started on prednisone forty milligrams daily and methotrexate fifteen milligrams per week with folic acid one milligram daily. His systemic features resolved rapidly — fevers gone within ten days of starting prednisone, rash gone, ferritin falling to four thousand at four weeks and to eight hundred at three months. The prednisone was tapered over eight months under close supervision. By month six he was on prednisone five milligrams daily and methotrexate fifteen milligrams weekly, feeling essentially normal. He returned to full work.

At his month-eleven rheumatology visit, Carlos reported that he had stopped methotrexate four weeks prior. He felt well. He had no fever, no rash, no serositis. His ferritin was six hundred — mildly elevated but stable. The rheumatologist examined him and found bilateral wrist synovitis, mild to moderate in the right wrist and mild in the left, and tenderness over the right index and middle MCP joints. This synovitis had been present, to varying degrees, since month four — persistent despite prednisone taper and methotrexate.

“El reumátol ogo me dijo antes que mi enfermedad era del año pasado,” Carlos explained to nurse Patricia Cisneros-Dominguez. “Entendí que ya me había curado de eso. Las muñecas me siguen molestando un poco, pero creo que es algo separado — artrosis de la edad quizás. No creí que el metotrexato para la enfermedad de Still todavía fuera necesario.”

(The rheumatologist told me before that my illness was from last year. I understood that I had already recovered from that. My wrists still bother me a little, but I think it is something separate — perhaps age-related arthritis. I did not think the methotrexate for Still’s disease was still necessary.)

Nurse Cisneros-Dominguez ordered urgent musculoskeletal ultrasound of the bilateral wrists and MCPs while Carlos was still in the clinic. The results, available within ninety minutes, showed moderate synovial hyperemia on Power Doppler in the right radiocarpal and right index MCP, and rice-body deposits — echogenic loose bodies in the right radiocarpal joint fluid — consistent with active AOSD synovitis. This was not osteoarthritis. She then sat with Carlos to explain what the ultrasound meant and why the methotrexate had been protecting him.

“Seor Medina-Ruiz, la ecografía que acabamos de hacer muestra que la inflamación en las muñecas y los nudillos no es artrosis — es la misma enfermedad de Still activa en las articulaciones. Y quiero explicarle algo importante sobre cómo la enfermedad de Still evoluciona en diferentes personas, porque no siempre sigue el mismo camino.”

(Mr. Medina-Ruiz, the ultrasound we just performed shows that the inflammation in the wrists and knuckles is not osteoarthritis — it is Still’s disease itself active in the joints. And I want to explain something important about how Still’s disease evolves in different people, because it does not always follow the same course.)

“¿Cómo puede seguir siendo Still si ya no tengo fiebre ni sarpullido?”

(How can it still be Still’s if I no longer have fever or rash?)

“Esa es una pregunta exactamente correcta. La respuesta es que la enfermedad de Still en adultos puede tomar tres formas diferentes. En la primera forma, el episodio — la fiebre, el sarpullido, la serositis, la ferritina alta — ocurre una vez y desaparece completamente, y no vuelve. En la segunda forma, ese tipo de episodio sistémico regresa de vez en cuando, como episodios repetidos. En la tercera forma — y es la forma que usted tiene, y que en este momento estamos viendo en la ecografía — los síntomas sistémicos como la fiebre y el sarpullido se resuelven, pero las articulaciones desarrollan una inflamación persistente que ya no es el mismo mecanismo del episodio agudo. Ya no es tanto IL-1beta. Es un tipo diferente de inflamación en las articulaciones — células T, TNF-alfa — que se parece más a la artritis reumatoide seronegativa. Esa inflamación no produce fiebre ni sarpullido. Pero si no se trata, erosiona los huesos de las muñecas y los nudillos en silencio. La única forma de detectarla es la ecografía y la radiografía anual, no cómo se siente usted día a día.”

(That is an exactly correct question. The answer is that Still’s disease in adults can take three different forms. In the first form, the episode — the fever, the rash, the serositis, the high ferritin — occurs once and disappears completely, and does not return. In the second form, that type of systemic episode returns from time to time, like repeated episodes. In the third form — and this is the form you have, and that we are now seeing on the ultrasound — systemic symptoms like fever and rash resolve, but the joints develop a persistent inflammation that is no longer the same mechanism as the acute episode. It is no longer mainly IL-1beta. It is a different type of inflammation in the joints — T cells, TNF-alpha — that more closely resembles seronegative rheumatoid arthritis. That inflammation does not produce fever or rash. But if untreated, it erodes the bones of the wrists and knuckles silently. The only way to detect it is ultrasound and annual x-ray, not how you feel day to day.)

“¿Y el metotrexato era para eso?”

“Exactamente. El metotrexato que usted tomaba estaba suprimiendo la actividad de las células T que alimentan esa inflamación articular persistente — a través de dos mecanismos distintos: uno que reduce directamente la capacidad de esas células de multiplicarse, y otro que produce una molécula llamada adenosina que reduce la inflamación en el tejido de las articulaciones. Cuando usted paró el metotrexato, esos dos mecanismos de protección desaparecieron. La inflamación en las muñecas y los nudillos continuó a su ritmo habitual. Los cambios en los huesos — las erosiones, el estrechamiento del espacio articular — se acumulan silenciosamente. Necesitamos hacer una radiografía de manos ahora para ver cúanto ha avanzado en el mes desde que paró el medicamento, y reiniciar el metotrexato hoy.”

(Exactly. The methotrexate you were taking was suppressing the activity of the T cells that feed that persistent joint inflammation — through two distinct mechanisms: one that directly reduces the ability of those cells to multiply, and another that produces a molecule called adenosine that reduces inflammation in the joint tissue. When you stopped methotrexate, those two protective mechanisms disappeared. The inflammation in the wrists and knuckles continued at its usual pace. Changes in the bones — erosions, narrowing of the joint space — accumulate silently. We need to do a hand x-ray now to see how much has progressed in the month since you stopped the medication, and restart methotrexate today.)

The hand and wrist x-ray showed no erosions at that point — they were in the structural-protection window. Methotrexate was restarted at fifteen milligrams per week. At the eighteen-month visit, Power Doppler synovitis had resolved and a follow-up wrist x-ray remained erosion-free. Carlos understood, and committed to, the surveillance protocol: annual x-ray, quarterly wrist ultrasound, and the clear distinction between the systemic and articular trajectories of his disease.

Scenario 3: Sofía Ramos-Cisneros — 26 years old, Chicago, Illinois

Sofía Ramos-Cisneros was a twenty-six-year-old second-year PhD student in biochemistry at a Chicago university who had been experiencing fevers for four weeks before diagnosis — initially dismissed as a flu-like illness by a walk-in clinic, then by student health. When the fevers persisted and she developed a distinctive rash and bilateral ankle and wrist swelling, an internist who had seen AOSD before made the diagnosis immediately: daily quotidian fevers to forty point one degrees Celsius, salmon-colored evanescent rash on her trunk that appeared each afternoon and faded by evening, seronegative bilateral ankle and wrist polyarthritis, ferritin sixty-two thousand nanograms per milliliter, bilateral minimal pleural effusions on chest CT, WBC nineteen thousand with neutrophilia, and negative comprehensive infectious and autoimmune workup.

She was started on prednisone seventy milligrams daily — one milligram per kilogram for her seventy-kilogram body weight — and referred urgently to rheumatology. At the three-week mark, she was dramatically improved: fever had resolved completely at day ten, the salmon rash had not appeared since day twelve, her wrist and ankle swelling was substantially reduced, and her ferritin had fallen from sixty-two thousand to four thousand two hundred nanograms per milliliter.

Sofía was a scientist. She read her own labs, searched the literature, and made her own decision about tapering. Over the following six weeks she reduced her prednisone from seventy milligrams to fifty milligrams at week four, then to thirty milligrams at week six. She did this without contacting the rheumatologist, reasoning that the rash was completely gone — which she interpreted as the clearest possible sign that the disease was resolving — and that high-dose prednisone was causing side effects she wanted to minimize: insomnia, mild weight gain, mood changes.

Her reasoning was scientifically sophisticated: “El sarpullido es una manifestación de inflamación activa. Si la inflamación está activa, el sarpullido está ahí. Si el sarpullido desapareció, la inflamación se redujo. Concluí que la dosis de prednisona era excesiva para el nivel de inflamación que me quedaba.”

(The rash is a manifestation of active inflammation. If inflammation is active, the rash is there. If the rash disappeared, the inflammation reduced. I concluded that the prednisone dose was excessive for the level of inflammation I had left.)

At week eight, she called the rheumatology clinic with new symptoms: fever returning at thirty-nine point eight degrees Celsius each evening, bilateral wrist and ankle arthritis worsening significantly, chest pain and dyspnea on exertion that had developed over three days. Nurse Roberto Fuentes-Herrera saw her urgently. Echocardiography showed a twelve-millimeter pericardial effusion — new compared to the trace effusion at diagnosis. Ferritin was ninety-five thousand nanograms per milliliter. Platelets were one hundred and eighty-two thousand — still normal but trending down from two hundred and thirty thousand three weeks earlier.

The situation required immediate explanation and immediate escalation of treatment. Nurse Fuentes-Herrera spoke with Sofía while the rheumatologist prepared the treatment plan.

“Sofía, sé que eres bioquímica y que tu raz onamiento sobre el sarpullido y la inflamación estaba basado en una lógica correcta en principio. Pero el sarpullido de la enfermedad de Still tiene una característica específica que hace que no pueda usarse como indicador de remisión, y entender esa característica es exactamente el tipo de información que deberíamos haberte dado desde el primer día.”

(Sofía, I know you are a biochemist and that your reasoning about the rash and inflammation was based on a logic that is correct in principle. But the rash of Still’s disease has a specific characteristic that makes it impossible to use as an indicator of remission, and understanding that characteristic is exactly the type of information we should have given you from day one.)

“¿Qué característica?”

“El sarpullido de la enfermedad de Still — ese color salmón rosado evanescente — no es una urticaria clásica. No lo producen las células que producen histamina. Lo producen los neutrófilos — los glóbulos blancos que van a la piel en respuesta a una señal específica que se llama IL-18. Y el sarpullido es evanescente — aparece y desaparece — por una razón mecánica muy específica: aparece cuando la fiebre sube, porque cuando la temperatura del cuerpo sube, los vasos sanguíneos de la piel se dilatan y los neutrófilos salen a la piel produciendo las rónchas. Cuando la fiebre baja — en las horas de la madrugada, cuando tienes menos temperatura — los vasos se contraen y las rónchas desaparecen en treinta a sesenta minutos. El sarpullido no estaba presente o ausente según si la inflamación era intensa o leve. Estaba presente o ausente según si tenías fiebre en ese momento.”

(The rash of Still’s disease — that evanescent salmon-pink color — is not classical urticaria. It is not produced by the cells that produce histamine. It is produced by neutrophils — the white blood cells that go to the skin in response to a specific signal called IL-18. And the rash is evanescent — appears and disappears — for a very specific mechanical reason: it appears when fever rises, because when body temperature rises, the blood vessels of the skin dilate and neutrophils exit into the skin producing the wheals. When fever falls — in the early morning hours when you have lower temperature — the vessels contract and the wheals disappear in thirty to sixty minutes. The rash was not present or absent based on whether inflammation was intense or mild. It was present or absent based on whether you had fever at that moment.)

Sofía was very still. “Entonces cuando el sarpullido desapareció en la semana tres, eso fue —”

“La prednisona bloqueando los neutrófilos que van a la piel. La prednisona bloquea esa señal IL-18 que activa los neutrófilos en la piel. Sin esa señal, sin neutrófilos en la piel, sin sarpullido. Pero la fuente de esa señal — los macrófagos y las células NK que producen IL-18 e IL-1beta — siguen activos. La prednisona los controla parcialmente. Cuando reduciste la dosis demasiado rápido, el control parcial se volvió insuficiente, la IL-1beta y la IL-18 regresaron a niveles que la dosis reducida ya no bloqueaba, y la enfermedad reflotó con la característica pericarditis que es una de las complicaciones más serias de esta enfermedad.”

(Prednisone blocking the neutrophils that go to the skin. Prednisone blocks that IL-18 signal that activates neutrophils in the skin. Without that signal, no neutrophils in the skin, no rash. But the source of that signal — the macrophages and NK cells that produce IL-18 and IL-1beta — remain active. Prednisone partially controls them. When you reduced the dose too quickly, the partial control became insufficient, IL-1beta and IL-18 returned to levels the reduced dose no longer blocked, and the disease reflared with the characteristic pericarditis that is one of the most serious complications of this disease.)

“¿Y el efecto adverso que me preocupaba — el insomnio, el estado de ánimo — no era una justificación para reducirla?”

“Los efectos adversos de la prednisona son reales y los efectos secundarios que describías son exactamente los que esperamos con dosis de setenta miligramos. Son una razón válida para hablar con el reum atólogo sobre acelerar levemente el inicio del tapering — con una conversación, con un plan conjunto, con monitoreo de laboratorio cada dos semanas. No son una razón para reducir la prednisona en veinte miligramos cada dos semanas sin aviso. La diferencia entre las dos opciones es la diferencia entre lo que estás experimentando ahora y no tener pericarditis.”

(The side effects of prednisone are real and the side effects you described are exactly what we expect with seventy milligrams doses. They are a valid reason to talk with the rheumatologist about slightly accelerating the start of tapering — with a conversation, with a joint plan, with laboratory monitoring every two weeks. They are not a reason to reduce prednisone by twenty milligrams every two weeks without warning. The difference between the two options is the difference between what you are experiencing now and not having pericarditis.)

Sofía was started on anakinra one hundred milligrams daily in addition to prednisone at sixty milligrams — the escalation her pericarditis required. Over the following twelve weeks, with close laboratory monitoring and a very structured taper plan, her pericardial effusion resolved, ferritin fell to twelve hundred, and the joint inflammation quieted. She remained on anakinra for sixteen months total before a supervised off-therapy trial.

She later told Nurse Fuentes-Herrera: “Entendí la inflamación como si fuera una función continua que el sarpullido mapeaba. Lo que no entendí es que el sarpullido evanescente no mapea la inflamación total — mapea un paso muy específico de ella que la prednisona bloquea muy fácilmente. El resto del proceso sigue activo deba jo.”

(I understood inflammation as if it were a continuous function that the rash mapped. What I did not understand is that the evanescent rash does not map total inflammation — it maps a very specific step of it that prednisone blocks very easily. The rest of the process continues active underneath.)

That framing — from a biochemist who had lived through the consequence of the misunderstanding — is exactly what the AOSD clinic nurse must convey in every first-presentation conversation, before the patient reaches for their own interpretation.

The AOSD adherence landscape the nurse must understand

The three patients in this post represent the three adherence challenges that are most consequential in adult-onset Still’s disease, and each requires the nurse to understand a different mechanistic layer of AOSD biology. Elena’s case requires the nurse to understand why ferritin normalization on anakinra is a pharmacodynamic effect, not a disease-state marker, and why stopping anakinra removes the specific protection against the amplification loop that produces MAS. Carlos’s case requires the nurse to understand the three-phenotype model of AOSD and to distinguish the systemic and articular trajectories clinically, using ultrasound as the tool that reveals chronic articular activity invisible to symptoms. Sofía’s case requires the nurse to understand the specific mechanism of the evanescent salmon rash — its neutrophilic urticarial dermatosis biology, its temporal co-occurrence with fever spikes, and why its suppression by prednisone at the level of skin neutrophil trafficking does not reflect suppression of the underlying NLRP3-caspase-1 circuit driving systemic disease activity.

The three cases share a structural logic that the nurse should be able to articulate in Spanish: every positive treatment response in AOSD — normalized ferritin, quieted joints, disappeared rash — is evidence of what the treatment is doing, not evidence of what the disease has become. The treatment is working means the disease is being controlled. It does not mean the disease has resolved. In AOSD specifically, the consequence of treating clinical improvement as evidence of resolution and stopping treatment is not slow silent progression but rapid, life-threatening deterioration through MAS.

The MAS risk is the feature that makes AOSD adherence uniquely high-stakes. In most inflammatory arthropathies, the cost of stopping treatment is disease flare, joint damage, or functional decline over months to years. In AOSD, the cost of stopping IL-1 blockade prematurely or tapering corticosteroids too fast can be a cytokine storm that progresses from fever to multi-organ failure within days. The nurse who understands this biology — the NLRP3-IL-1β-IL-18-macrophage-hemophagocytosis cascade, the warning signs of early MAS (rapidly rising ferritin, falling platelets, rising LDH, D-dimer), and the emergency threshold (“ferritina por encima de cincuenta mil y plaquetas cayendo — urgencias inmediatamente”) — is operating as a first-line defense against one of the most dangerous outcomes in inflammatory medicine.

The five statements every adult-onset Still’s disease clinic nurse should be able to make clearly in Spanish:

First: ferritin normalization on anakinra is the drug working, not the disease resolved. “La ferritina normal es la prueba de que el anakinra funciona — no la prueba de que la enfermedad desapareció. Las células que producen la señal que causa esa ferritina siguen activas, controladas por el medicamento. Cuando se para el anakinra, esa señal vuelve en días.” (Normal ferritin is the proof that anakinra is working — not the proof that the disease disappeared. The cells that produce the signal that causes that ferritin remain active, controlled by the medication. When anakinra is stopped, that signal returns within days.)

Second: MAS is the specific complication that makes AOSD different from other joint diseases. “La enfermedad de Still tiene una complicación que la distingue de otras enfermedades inflamatorias de las articulaciones: el síndrome de activación macrofágica. Es una tormenta de citoquinas que puede ocurrir cuando el tratamiento se interrumpe, con mortalidad del diez al veinte por ciento en cuidados intensivos. Las señales de alerta son fiebre que no cede, ferritina que sube rápidamente, y plaquetas que bajan. Si tiene esos tres síntomas al mismo tiempo — urgencias inmediatamente.” (Still’s disease has a complication that distinguishes it from other inflammatory joint diseases: macrophage activation syndrome. It is a cytokine storm that can occur when treatment is interrupted, with ten to twenty percent mortality in intensive care. The warning signs are fever that does not respond, ferritin rising rapidly, and falling platelets. If you have those three symptoms simultaneously — emergency room immediately.)

Third: the three AOSD phenotypes require different treatment durations. “Esta enfermedad puede tomar tres caminos diferentes. En uno, el episodio ocurre una vez y no regresa. En otro, ocurre en episodios repetidos. En el tercero, las articulaciones quedan inflamadas de manera persistente aunque la fiebre y el sarpullido desaparezcan. Su reumatólogo necesita saber en cuál camino está usted para determinar por cuánto tiempo es necesario el tratamiento. No asuma que porque la fiebre y el sarpullido mejoraron, la enfermedad ha terminado.” (This disease can take three different paths. In one, the episode occurs once and does not return. In another, it occurs in repeated episodes. In the third, the joints remain persistently inflamed even when fever and rash disappear. Your rheumatologist needs to know which path you are on to determine how long treatment is necessary. Do not assume that because fever and rash improved, the disease is over.)

Fourth: the salmon rash disappearing on prednisone is suppression not remission. “El sarpullido salmón de la enfermedad de Still desaparece con la prednisona porque la prednisona bloquea los glóbulos blancos que van a la piel. Pero las células que producen la inflamación sistémica — la fiebre, la pericarditis, las articulaciones — siguen activas. El sarpullido que desaparece no es una señal de que se puede reducir la prednisona por iniciativa propia. El plan de reducción debe hacerse con el reum atólogo, no solo.” (The salmon rash of Still’s disease disappears with prednisone because prednisone blocks the white blood cells that go to the skin. But the cells that produce the systemic inflammation — the fever, the pericarditis, the joints — remain active. The disappearing rash is not a sign that prednisone can be reduced independently. The reduction plan must be made with the rheumatologist, not alone.)

Fifth: the prednisone taper schedule in AOSD is medically supervised and takes twelve months. “La prednisona en la enfermedad de Still no se reduce como un antibiótico que se termina cuando uno se siente mejor. El protocolo estándar es mantener la dosis terapéutica completa por cuatro a seis semanas, y después reducir lentamente — no más del diez por ciento de la dosis actual cada dos a cuatro semanas. En total, el proceso toma doce meses como mínimo desde el inicio. La reducción sin supervisión médica puede desencadenar una recaída severa con complicaciones serias.” (Prednisone in Still’s disease is not reduced like an antibiotic that is finished when one feels better. The standard protocol is to maintain the full therapeutic dose for four to six weeks, then reduce slowly — no more than ten percent of the current dose every two to four weeks. In total, the process takes a minimum of twelve months from initiation. Reduction without medical supervision can trigger a severe relapse with serious complications.)

Adult-onset Still’s disease is rare enough that many clinic nurses will see only a few cases in their career. It is dangerous enough that those few cases require an unusually deep understanding of the disease biology — specifically the NLRP3-caspase-1-IL-1β-IL-18 amplification loop, the MAS complication, and the specific ways that clinical improvement in AOSD can be misread as treatment completion. The AOSD clinic nurse who understands this biology and can explain it clearly in Spanish — using the ferritin as a pharmacodynamic marker, identifying the chronic articular phenotype, and explaining exactly why the salmon rash disappearing is not the signal the patient thinks it is — is the clinical professional most likely to prevent a MAS episode before it begins.

“La fiebre que desapareció, la ferritina que bajó, el sarpullido que no se ve: todas son buenas noticias porque el tratamiento está funcionando. Son la razón para continuar — no para parar.”

(The fever that disappeared, the ferritin that fell, the rash that is not visible: all are good news because treatment is working. They are the reason to continue — not to stop.)

That sentence, said with mechanistic understanding and in the language the patient speaks, is the foundation of safe AOSD management.

Internal links: Spanish for rheumatology clinic nurses · Spanish for systemic lupus erythematosus clinic nurses · Spanish for Sjögren’s syndrome clinic nurses · Spanish for vasculitis clinic nurses